Scopus Biopharma Stock Shares Owned By Insiders
Scopus Biopharma fundamentals help investors to digest information that contributes to Scopus Biopharma's financial success or failures. It also enables traders to predict the movement of Scopus OTC Stock. The fundamental analysis module provides a way to measure Scopus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scopus Biopharma otc stock.
Scopus |
Scopus Biopharma OTC Stock Shares Owned By Insiders Analysis
Scopus Biopharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Scopus Biopharma Shares Owned By Insiders | 50.66 % |
Most of Scopus Biopharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scopus Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 50% of Scopus Biopharma are shares owned by insiders. This is 233.73% higher than that of the Healthcare sector and 257.26% higher than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Scopus Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in shares owned by insiders category among its peers.
Scopus Fundamentals
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 | ||||
| Current Valuation | 1.18 M | ||||
| Shares Outstanding | 21.09 M | ||||
| Shares Owned By Insiders | 50.66 % | ||||
| Shares Owned By Institutions | 2.15 % | ||||
| Number Of Shares Shorted | 23.77 K | ||||
| Price To Book | 2.42 X | ||||
| EBITDA | (26.18 M) | ||||
| Net Income | (26.95 M) | ||||
| Cash And Equivalents | 1.16 M | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 2.54 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (0.26) X | ||||
| Cash Flow From Operations | (11.42 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (1.51) X | ||||
| Target Price | 12.0 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 2.17 M | ||||
| Total Asset | 8.19 M | ||||
| Z Score | -9.9 | ||||
| Net Asset | 8.19 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |